张金良教授运用组药治疗肝癌经验

“组药”是以中医理论为指导,以辨证论治为基础,根据药物的性味、归经、相互作用与配伍规律,在长期临床实践基础上经过不断提炼、筛选出来的药物组合。组药一般由3~4味药物组成,其数量与功用均多于对药。其关键在于“组”,即药物的最佳配伍组合;其特点在于“精”,即追求组合的精炼,避免臃肿。

基于数据挖掘的补肾法治疗类风湿关节炎用药规律研究

目的:探索补肾法治疗类风湿关节炎的用药规律,从“理-法-方-药”角度阐释补肾法治疗类风湿关节炎的内涵,为临床治疗提供依据。方法:计算机检索中国知网、万方、维普、PubMed、Science Direct、Cochrane Library、Web of science数据库,筛选补肾法治疗类风湿关节炎的文献,构建补肾方剂数据库,根据《中国药典》及《中华本草》对中药名称进行规范处理。运用Microsoft Excel进行频数统计和功效分类统计,IBM SPSS Modeler实现Apriori建模进行关联规则分析,Cytoscape计算拓扑学特征并形成复杂网络,IBM SPSS Statistics对高频中药进行系统聚类分析以及因子分析。结果:最终纳入144篇文献,包含111首方剂,涉及156味中药。频次统计结果显示,使用频次> 20次的中药有25味,前5味为熟地黄、淫羊藿、白芍、续断、补骨脂,功效分类以补益药、祛风湿药、活血化瘀药和清热药为主。经设置后Apriori算法最终产生560条规则,常见组合有熟地黄-骨碎补-威灵仙、熟地黄-补骨脂-淫羊藿、桂枝-白芍-续断。聚类分析得到具有同质性的5组中药药组,因子分析最终得到公因子8个,补肾祛寒治尪汤加减是多个补肾中药复方的共同因子。结论:补肾法治疗类风湿关节炎的核心要点是扶正祛邪、标本同治,扶正以补肾壮骨、温阳散寒为主,重视调和营卫,祛邪包括祛风除湿、活血化瘀、清解郁热,并灵活配伍藤类药和虫类药通经活络。

三种中药组方对快速上浮脱险减压病大鼠肺组织炎症反应的影响

目的 观察3种中药组方对快速上浮脱险减压病大鼠肺组织炎症反应的影响,筛选出疗效确切的药组.方法 100只实验大鼠分为5组：正常组、模型组、1号药组、2号药组、3号药组,每组20只,3个给药组给予相应的中药配方颗粒灌胃,10 d后,除正常组外,其余各组模拟快速上浮脱险诱导减压病模型.观察各组大鼠生存率、肺组织病理、血清和肺组织IL-1、TNF-α的变化情况.结果 与模型组比较,3个给药组大鼠死亡率下降,2、3号药组肺泡壁增厚程度和肺间质充血水肿程度明显减轻.2号和3号药组血清中IL-1、TNF-α含量[（145.84 ±2.10） ng/L,（249.71 ±2.89） ng/L;（123.71 ±1.74） ng/L,（229.23 ±8.74） ng/L]与对照组[（183.18±2.41） ng/L,（300.33±6.03） ng/L]比较均显著下降,差异有统计学意义（P＜0.01）;组织匀浆中IL-1与TNF-α含量亦明显下降（P＜0.01或P＜0.05）.结论 2、3号药组对快速上浮脱险减压病大鼠肺组织的炎症反应有明显的改善作用.本研究为2、3号药组用于减压病的治疗提供了实验依据支撑.

Pharmacologic mechanisms mining and prediction of Xiaoer Qixing Cha Formulae in the treatment of infantile functional dyspepsia based on chemical analysis by UPLC-QTOF/MS and interactive network pharmacology

Objective: To explore the main chemical compounds in Xiaoer Qixing Cha Formulae (XQCF), and investigate its mechanisms for the treatment of infantile functional dyspepsia (IFD). Methods: The chemical components were identified by UPLC-QTOF/MS analytic technique. Targets of the compounds were screened from TCMSP and SWISS database, and disease targets were screened from OMIM and TTD online database. Candidate targets of compounds were mapped to the disease targets as predict therapeutic targets for XQCF. Several networks were constructed and analyzed by Cytoscape ver. 3.2.1. Meanwhile, prescription compatibility in XQCF was interpreted from the network perspective based on distribution of the number of targets. Furthermore, Gene Ontology (GO) enrichment analysis and KEGG pathway analysis were operated via Clue Go to illustrate complex relationships between the potential targets and pharmacological mechanisms. Results: A total of fifty-three compounds were recognized or tentatively characterized belonging to XQCF based on MS data and online chemical database. Sixty-three therapeutic targets were screened. AKT1, FOS, SLC6A4, COMT and 5-HT receptors were focused as therapeutic targets of XQCF. Pathways including carbohydrate digestion and absorption, serotonergic synapse, calcium signaling pathway and cAMP signaling pathway were predicted as significant regulatory pathways. The results indicated that the predicted targets and pathways related in brain-gut axis to a great extent, which could be potential pharmacological mechanism of XQCF for the treatment of IFD. Conclusions: The findings in this study provided the experimental and theoretical basis for further research for XQCF. Those also illustrated a reasonable method worth intensive study on pharmacodynamic mechanisms of TCM Formulae.